---
figid: PMC3736724__nihms500300f1
figtitle: Tyrosine kinase (TYK) targeting growth factor and proliferation pathways
organisms:
- NA
pmcid: PMC3736724
filename: nihms500300f1.jpg
figlink: /pmc/articles/PMC3736724/figure/F1/
number: F1
caption: Tyrosine kinase (TYK) targeting growth factor and proliferation pathways.
  Regulation of endothelial cell functions (migration, proliferation, vascular permeability,
  remodeling) is determined by the activity of protein kinases on the endothelium.
  Growth factor, angiogenesis/proliferation, and integrin pathways lead to a chain
  of events that ultimately produce changes in vascular permeability or remodeling.
  Thus, modulation with therapeutic agents such as statins and sorafenib corresponds
  to protein tyrosine kinase (PTK), which inhibits the RAS/RAF-1/MAPK pathway, and
  vascular endothelium growth factor receptor-2 (VEGFR-2) (KDR) blocker prevents vascular
  remodeling and proliferation. Statins have also been shown to modulate integrin
  signaling and VEFGR pathways to ultimately affect vascular function
papertitle: Receptor Tyrosine Kinase Inhibitors in Rodent Pulmonary Hypertension.
reftext: Liliana Moreno-Vinasco, et al. Adv Exp Med Biol. ;661:419-434.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9395938
figid_alias: PMC3736724__F1
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC3736724__F1
ndex: 5f546b69-df05-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3736724__nihms500300f1.html
  '@type': Dataset
  description: Tyrosine kinase (TYK) targeting growth factor and proliferation pathways.
    Regulation of endothelial cell functions (migration, proliferation, vascular permeability,
    remodeling) is determined by the activity of protein kinases on the endothelium.
    Growth factor, angiogenesis/proliferation, and integrin pathways lead to a chain
    of events that ultimately produce changes in vascular permeability or remodeling.
    Thus, modulation with therapeutic agents such as statins and sorafenib corresponds
    to protein tyrosine kinase (PTK), which inhibits the RAS/RAF-1/MAPK pathway, and
    vascular endothelium growth factor receptor-2 (VEGFR-2) (KDR) blocker prevents
    vascular remodeling and proliferation. Statins have also been shown to modulate
    integrin signaling and VEFGR pathways to ultimately affect vascular function
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FLT1
  - FGF2
  - FGF13
  - VEGFB
  - VEGFA
  - VEGFC
  - VEGFD
  - PGF
  - PIGF
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - NRP1
  - NELL1
  - KDR
  - ITGAV
  - ITGB1
  - ITGB2
  - ITGB3
  - ITGB4
  - ITGB5
  - ITGB6
  - ITGB7
  - ITGB8
  - ITGBL1
  - CRK
  - CSK
  - PLCG1
  - PLCG2
  - SOS1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - AKT1
  - AKT2
  - AKT3
  - RAF1
  - RNASE3
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - NOS3
  - NANOS3
  - MAP2K1
  - NFKB1
  - Nitric Oxide
  - Cancer
  - Noonan syndrome
---
